ClinicalTrials.gg
CompletedNCT00239213Updated Oct 31, 2006

Catechin Gargling for Influenza Infection

An interventional study of catechin extracts (health food) in Influenza Infection, sponsored by University of Shizuoka. Completed at 3 sites in Japan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2006-10-31.

Sponsored by University of Shizuoka · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Influenza, Human with a site in Japan — 4 open to participants now, 4 under way, 3 of them phase 3. Influenza, Human · Japan.

Enrollment
13th of 40
400 · median 169
Started
2005
the only one that year
No phase
5 of 42
1 open now
Registered
1st of 42
by date
Lead sponsor
3 of 42
University of Shizuoka

Among the 42 studies in Influenza, Human with a site in Japan, this one is the 13th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2005, is one of 5 with no phase, and was the 1st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 42 studies in Influenza, Human with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Influenza, Human with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to clarify the preventive effects of catechin gargling on the influenza infection.

Read the detailed description

In-vitro experimental studies have revealed that tea catechin extracts induce preventive effects on influenza infection. However, few studies have been conducted on the effects of tea gargling on influenza infection, and the clinical evidence is unclear. Also there have been no studies reported on the gargling effects with tea catechin extracts on the prevention of influenza infection.

03

Conditions studied

  • Influenza Infection

Browse trials for

Keywords

  • catechins
  • gargling
  • healthy volunteers
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy volunteers
  • aged 20 to 65 years old
  • obtained written informed concent before participation
  • inoculated with influenza vaccine before entering the study

Exclusion criteria

Exclusion Criteria:

  • other gargling except water during the study
  • possessing tea allergy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
400 participants

Interventions

  • Drugcatechin extracts (health food)
06

What researchers measure

Primary outcomes

  1. Incidence rates of influenza infection during the study

Secondary outcomes

  1. severity of symptoms including complications and hospitalization

07

Study locations

3 sites
  • Seirei Hamamatsu General Hospital
    Hamamatsu, Shizuoka 430-8558, Japan
  • White Cross Nursing Home
    Higashi Murayama, Tokyo 189-0021, Japan
  • Shizuoka General Hospial
    Shizuoka, 420-8527, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2005
First posted
Oct 14, 2005
Start
Nov 2005
Completion
Apr 2006
Last update
Oct 31, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Oct 31, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00239213
Lead sponsor
University of Shizuoka
Collaborators
Shizuoka General Hospital, Seirei Hamamatsu General Hospital, White Cross Nursing Home
First posted
Oct 14, 2005
Start date
Nov 2005
Completion
Apr 2006
Last update
Oct 31, 2006

Study contacts

Hiroshi Yamada, MD, PhD
principal investigator · University of Shizuoka
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion